Advertisement
Screener

Vaxart, Inc. (VXRT) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Vaxart, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Vaxart, Inc. (VXRT) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $2.96 million for the 12-month period ending 2025-12-31, per its S-1 filed 2026-05-08.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-05-08

  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2012-12-31 was $958.00K, a 133.66% increase year-over-year.
  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2011-12-31 was $410.00K.
  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2017 was $8.40M, a 10.64% decline from fiscal 2016.
  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2016 was $9.40M, a 1075.00% increase from fiscal 2015.
  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2015 was $800.00K, a 80.49% decline from fiscal 2014.
  • Vaxart, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2014 was $4.10M, a 2.38% decline from fiscal 2013.
Period endEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 monthEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 monthEffective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month
2025-12-31$2.96M
S-1 · filed 2026-05-08
2017-06-30$8.40M
10-K · filed 2017-09-01
2016-06-30$9.40M
10-K · filed 2017-09-01
2015-06-30$800.00K
10-K · filed 2016-09-13
2014-06-30$4.10M
10-K · filed 2016-09-13
2013-06-30$4.20M
10-K · filed 2015-09-11
2012-12-31$958.00K
10-Q · filed 2013-02-11
$2.00M
10-Q · filed 2013-02-11
2012-06-30$2.80M
10-K · filed 2014-09-30
2011-12-31$410.00K
10-Q · filed 2013-02-11
$786.00K
10-Q · filed 2013-02-11
2011-06-30$9.80M
10-K · filed 2013-09-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
EXOZYMES INC. (EXOZ)United States$0.058B